

China Biologic Products, Inc.
Form 4
June 08, 2016

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Fang Min

(Last) (First) (Middle)

C/O CBPO, 18/F, JIALONG
INTERNATIONAL, BUILDING, 19
CHAOYANG PARK ROAD

(Street)

BEIJING, F4 100125

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
China Biologic Products, Inc.
[CBPO]

3. Date of Earliest Transaction
(Month/Day/Year)
06/08/2016

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner
☐ Officer (give title below) ☐ Other (specify below)

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
Common stock	06/08/2016		S	2,775,000 (1)	D \$ 111 1,312,200 (2) (3) (4)	I	See footnotes (1) (2) (3) (4) (5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form
displays a currently valid OMB control
number.**

SEC 1474
(9-02)

Edgar Filing: China Biologic Products, Inc. - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Benef Own Follo Repor Trans (Instr
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Fang Min
C/O CBPO, 18/F, JIALONG INTERNATIONAL
BUILDING, 19 CHAOYANG PARK ROAD
BEIJING, F4 100125

X

Signatures

/s/ Min Fang

06/08/2016

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The shares of common stock, \$0.0001 par value per share (the "Common Stock") reported in Column 4 of this Form 4 were sold pursuant to that certain underwriting agreement dated June 2, 2016 (the "Underwriting Agreement"), entered into by and among China Biologic Products, Inc. (the "Issuer"), Warburg Pincus Private Equity X, L.P., a Delaware limited partnership ("WP X"), Warburg Pincus X Partners, L.P., a Delaware limited partnership ("WPP X," together with WP X, the "Funds"), WP X Biologics LLC, a Delaware limited liability company ("WP X B"), and Morgan Stanley & Co. International plc, as the underwriter named in the Underwriting Agreement (the "Underwriter"). At the closing of the transaction contemplated under the Underwriting Agreement, on June 8, 2016, WP X B and the Funds sold an aggregate of 2,775,000 shares of Common Stock to the Underwriter for a purchase price of \$308,025,000.00, or \$111.00 per share.

(2) The 1,312,200 shares of the Common Stock of the Issuer are held by WP X B, WP X and holder of 96.9% of the equity interest in WP X B, and WPP X and holder of 3.1% of the equity interest in WP X B. Warburg Pincus X, L.P., a Delaware limited partnership ("WP X LP"), is the general partner of each of the Funds, Warburg Pincus X GP L.P., a Delaware limited partnership ("WP X GP"), is the general partner of WP X LP, WPP GP LLC, a Delaware limited liability company ("WPP GP"), is the general partner of WP X GP, Warburg Pincus Partners, L.P., a Delaware limited partnership ("WP Partners"), is the managing member of WPP GP, Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP LLC"),

(3) (Continued from Footnote 2) is the general partner of WP Partners, Warburg Pincus & Co., a New York limited liability company, is the managing member of WPP GP LLC, and Warburg Pincus LLC, a New York limited liability company ("WP LLC"), manages each

Edgar Filing: China Biologic Products, Inc. - Form 4

of the Funds. Charles R. Kaye and Joseph P. Landy are each Managing General Partners of WP and Managing Members and Co-Chief Executive Officers of WP LLC and may be deemed to control WP X B, the Funds, WP X LP, WP X GP, WPP GP, WP Partners, WPP GP LLC, WP and WP LLC. By reason of the provisions of Rule 16a-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), WP X LP, WP X GP, WPP GP, WP Partners, WPP GP LLC, WP, WP LLC, Mr. Kaye and Mr. Landy may be deemed to be the beneficial owners of any securities that may be beneficially owned by WP X B and the Funds.

- (4) (Continued from Footnote 3) Each of WP X LP, WP X GP, WPP GP, WP Partners, WP GP LLC, WP, WP LLC, Mr. Kaye and Mr. Landy disclaim beneficial ownership of all shares of Common Stock that may be deemed to be beneficially owned by WP X B and the Funds, except to the extent of any indirect pecuniary interest therein.

- (5) Mr. Fang is a Managing Director and Member of WP LLC. As such, Mr. Fang may be deemed to have an indirect pecuniary interest (within the meaning of Rule 16a-1 under the Exchange Act) in an indeterminate portion of the securities reported as beneficially owned by the Funds and WP X B. Mr. Fang disclaims beneficial ownership of such securities, except to the extent of any direct pecuniary interest therein. Mr. Fang does not directly own any shares of Common Stock of the Issuer.

Remarks:

* This Form 4 shall not be deemed an admission that the Reporting Person or any other person referred to herein is a beneficial owner.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.